AstraZeneca, R&D Mölndal and Manufacturing Södertälje
Mölndal, Sweden is one of our three strategic global R&D centres with connections to Karolinska Institutet and Medicon Valley. Södertälje is one of our principal small molecule manufacturing facilities.
Macclesfield, in the north-west of England, is our second largest global manufacturing site and our European centre for packing. In 2013 we announced plans to invest $190 million to construct a new facility to continue production of Zoladex.
AstraZeneca, MedImmune biologics science unit Cambridge
MedImmune, our biotech unit focusing on innovation and discovery research in biologics, has an estabished presence within Cambridge. In June 2013, we confirmed that our new UK-based global R&D centre and corporate headquarters will be located at the Cambridge Biomedical Campus with a planned investment of around $515 million and is expected to be completed by 2016.
Your email address will only be used to provide you with services from AstraZeneca that you requested. You can opt out for email subscriptions at any time. Your personal information will not be provided to any third party without your permission.
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.
Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.
You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information.
I have read this warning and will not be using any of the contained product information for clinical purposes.